Please login to the form below
Roivant
This page shows the latest Roivant news and features for those working in and with pharma, biotech and healthcare.
Myovant preps US filing for relugolix in prostate cancer
companies in the Roivant Sciences group headed by entrepreneur Vivek Ramaswamy – in September.
Latest news
-
Sumitomo Dainippon goes big on biotech with $3bn Roivant deal
The five companies Sumitomo is set to take over from Roivant include Myovant, Urovant, Enzyvant, Altavant and another undisclosed spinout company. ... in this alliance,” said Vivek Ramaswamy, founder and chief executive officer of Roivant.
-
Myovant has second phase 3 trial to back its uterine fibroids drug
The company, part of the Swiss Roivant group headed by Vivek Ramaswamy, says the LIBERTY 2 trial showed a 71.2% response rate for once-daily relugolix in women with uterine
-
Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease
Roivant Sciences subsidiary Metavant licensed US and European rights to the drug last year for $35m upfront, a $15m equity investment and up to $500m in milestone payments.
-
Myovant’s fibroids drug clears phase 3 trial, but shares sink
The company, part of the Swiss Roivant group headed by Vivek Ramaswamy, reported that 73% of women with uterine fibroids and heavy menstrual bleeding who were treated with relugolix responded to
-
Bluebird and Alexion veterans launch cell and gene venture ElevateBio
The model is similar to other recent launches in the biotech entrepreneur field, such as Vivek Ramaswamy’s Roivant and its host of 'vant’ specialist firms, aiming to create agile organisations
More from news
Approximately 7 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Pharma deals in May 2015
110. Arena Pharmaceuticals/ Roivant Sciences. Licence agreement. For Nelotanserin a 5-HT2A receptor P2 in behavioural and neuropsychiatric disturbances.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Axovant poaches Allergan’s and Teva’s chief medical and science officers
I am also eager to leverage the Roivant platform to accelerate the development of Axovant’s pipeline.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- First trial of a vaccine against Alzheimer’s launches
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- AbbVie/Allergan merger faces renewed public opposition despite divestments
- AbbVie/Allergan's merger faces public opposition
- AstraZeneca officially opens new R&D facility in UK
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
